OptiNose
OPTN
OPTN was delisted on the 20th of May, 2025.
49 hedge funds and large institutions have $166M invested in OptiNose in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
49% more capital invested
Capital invested by funds: $112M → $166M (+$54.5M)
11% more funds holding
Funds holding: 44 → 49 (+5)
0% less ownership
Funds ownership: 3.68% → 3.67% (-0%)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$652K |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$515K |
| 3 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
+$326K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$271K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$760K |
| 2 |
Millennium Management
New York
|
-$546K |
| 3 |
Morgan Stanley
New York
|
-$408K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$169K |
| 5 |
Goldman Sachs
New York
|
-$156K |
OPTN Hedge Fund Activity: Q2 2022 in Review
49 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in OptiNose (OPTN) for Q2 2022, worth a combined $166M — up 49% from $112M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OPTN positions and 3 closed out — a net gain of 5 holders — while 14 added to existing stakes and 18 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $652K. The largest seller was Stonepine Capital Management, cutting an estimated $760K.
- 49 institutional investors held OptiNose (OPTN) as of Q2 2022, up from 44 in Q1 2022.
- Funds reported $166M of OptiNose stock for Q2 2022, up 49% quarter-over-quarter.
- 8 funds opened new OptiNose positions in Q2 2022 and 3 closed out, a net change of +5 holders.
- The largest OptiNose buyer in Q2 2022 was EAM Investors, an estimated $652K added.
- The largest OptiNose seller in Q2 2022 was Stonepine Capital Management, an estimated $760K sold.
Based on aggregated 13F filings for Q2 2022.